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ABSTRACT
The actin and microtubule cytoskeletons are critically important for cancer cell 
proliferation, and drugs that target microtubules are widely-used cancer therapies. 
However, their utility is compromised by toxicities due to dose and exposure. To 
overcome these issues, we characterized how inhibition of the actin and microtubule 
cytoskeleton regulatory LIM kinases could be used in drug combinations to increase 
efficacy. A previously-described LIMK inhibitor (LIMKi) induced dose-dependent 
microtubule alterations that resulted in significant mitotic defects, and increased the 
cytotoxic potency of microtubule polymerization inhibitors. By combining LIMKi with 
366 compounds from the GSK Published Kinase Inhibitor Set, effective combinations 
were identified with kinase inhibitors including EGFR, p38 and Raf. These findings 
encouraged a drug discovery effort that led to development of CRT0105446 and 
CRT0105950, which potently block LIMK1 and LIMK2 activity in vitro, and inhibit 
cofilin phosphorylation and increase αTubulin acetylation in cells. CRT0105446 and 
CRT0105950 were screened against 656 cancer cell lines, and rhabdomyosarcoma, 
neuroblastoma and kidney cancer cells were identified as significantly sensitive to 
both LIMK inhibitors. These large-scale screens have identified effective LIMK inhibitor 
drug combinations and sensitive cancer types. In addition, the LIMK inhibitory 
compounds CRT0105446 and CRT0105950 will enable further development of LIMK-
targeted cancer therapy.
INTRODUCTION
The LIM kinases 1 and 2 (LIMK1 and LIMK2) 
are central regulators of cytoskeletal dynamics [1, 
2]. Although their regulation of cofilin activity and 
filamentous actin (F-actin) stability have been extensively 
studied [3], they also contribute to microtubule dynamics 
via less well characterized mechanisms [4-6]. Given 
their cytoskeleton-associated functions and indications 
of elevated expression in various cancer types, research 
has largely focussed on their roles in tumor cell migration, 
invasion and metastasis [7-9]. More recent studies 
have shown that the LIM kinases modulate additional 
activities that contribute to cancer development, including 
cell proliferation and survival [4-6]. LIMK activity 
also contributes to cancer cell resistance to various 
chemotherapeutic agents and ionizing radiation, while 
blocking LIMK activity reverses this resistance or even 
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increases sensitivity [10-14]. These observations have 
spurred efforts directed towards the discovery of LIMK 
inhibitors as potential cancer therapeutic agents that 
could be used as single agents or as part of combination 
therapies [15-17].
In recent years, the focus of cancer drug discovery 
has evolved from developing chemotherapeutics that 
could be widely-used across multiple cancers to treatments 
tailored for specific tumor types. In particular, this has led 
to the development of targeted therapies that utilise unique 
molecular properties identified in malignant cells to 
preferentially target tumor cells, while reducing potential 
detrimental effects on normal cells [18]. However, 
molecularly-targeted therapies have not been as successful 
as originally anticipated, with high rates of failure and 
limited numbers of patients that manifest positive clinical 
responses.
In order to improve chances for targeted therapy 
success, two strategies have been considered. Firstly, as 
an alternative or complement to molecularly-targeted 
therapies, other proteins or biological processes may 
be important targets because of accessory or auxiliary 
functions they provide. For example, stresses induced 
by oncogenic transformation often lead to reliance upon 
heat-shock protein chaperones, such that inhibition of 
heat shock proteins including Hsp90, Hsp70 and Hsp27 
has become a large area of cancer drug development 
[19]. Similarly, associations between human cancers and 
alterations in the actin and microtubule cytoskeletons 
have been well documented [20], suggesting that drugs 
targeting cytoskeleton regulators might be efficacious for 
the treatment of certain tumor types [15-17]. Unbiased 
screening may reveal drug sensitivities that reflect 
dependence on these auxiliary functions that would not be 
identified by genetic profiling.
A number of small molecule LIMK inhibitors have 
been discovered [6, 21-25] and several have been reported 
to be efficacious as single agent therapeutics on cancer 
cells including: breast [6, 26], pancreatic [27], prostate 
[5], cervical adenocarcinoma [6], fibromatosis [28], 
leukemia [4, 6] and glioma [29]. To identify how LIMK 
inhibitors might best be utilized, we carried out two cell-
based screens. In the first, a LIMK inhibitor was combined 
with microtubule-targeting drugs, or the GSK published 
kinase inhibitor set (PKIS) of 366 small molecule kinase 
inhibitors [30], to identify combinations with positive 
interactions. In the second, two novel LIMK inhibitors 
we developed were used to screen 656 tumor cell lines to 
identify cancer types with significant sensitivity to their 
anti-proliferative effects. These large-scale and unbiased 
cell-based screens revealed a range of drug combinations 
that could be considered for further development, and 
identified tumor types with significant sensitivity to LIMK 
inhibition.
RESULTS
LIMK inhibition affects microtubule organization 
and mitosis
To determine how LIMK inhibition affects cancer 
cell proliferation, we made use of the small molecular 
inhibitor N-{5-[2-(2,6-Dichloro-phenyl)-5-difluoromethyl-
2H-pyrazol-3-yl]-thiazol-2-yl}-isobutyramide (compound 
3 in [21]; hereafter referred to as LIMKi) that blocks both 
LIMK1 (7 nM IC
50 
in vitro) and LIMK2 (8 nM IC
50
) 
activity. The results of selectivity profiling of LIMKi 
at 10 µM against 287 kinases [21] using KINOMEscan 
technology [31] was mapped onto a kinome phylogenetic 
tree [32] in Supplemental Figure 1A. To compare 
specificity quantitatively, the LIMKi S(35) selectivity 
score (a ratio of kinases inhibited by > 65% relative to 
the total number of kinases) was compared to S(35) 
values for 38 additional kinase inhibitors, including 7 
FDA licenced drugs, at 10 µM (Supplemental Figure 1B; 
LIMKi indicated in blue). Furthermore, the inset graph in 
Supplemental Figure 1B of LIMKi S(1) (i.e. proportion of 
kinases inhibited by 99%), S(10) (proportion of kinases 
inhibited by 90%) and S(35) selectivity scores indicates 
the high selectivity of LIMKi. At 10 µM LIMKi, only 
13 kinase targets (ADCK3, ALK4, AMPKα1, AMPKα2, 
BRSK1, BRSK2, DCAMKL1, DCAMKL2, DDR1, 
FGFR1, PAK3, PCTAIRE1) in addition to LIMK1 and 
LIMK2 were inhibited by > 65% [21]. We validated the 
dose-dependent effect of LIMKi on inhibiting LIMK 
activity by treating A549 human lung adenocarcinoma 
epithelial cells for 18 hours with DMSO vehicle or 1, 
3 or 10 µM LIMKi [9, 21] and western blotting for 
phosphorylation of cofilin, a well-characterized LIMK 
substrate [9] (Figure 1A). We next examined how 
microtubule organization was affected by LIMKi in non-
dividing cells by treating A549 cells for 24 hours with 
DMSO vehicle or 3 or 10 µM LIMKi. Representative 
images show progressive changes in microtubule 
morphology with increasing LIMKi dose (Figure 1B). 
To determine whether this effect was associated with 
changes in microtubule stability, we analysed the effect of 
LIMKi on αTubulin acetylation [33]. Confocal images of 
A549 cells co-stained with antibodies against acetylated-
αTubulin (Figure 1C; green) and total αTubulin (Figure 
1C; red) revealed a concentration-dependent increase 
in αTubulin acetylation after 24-hour LIMKi treatment. 
Quantification of fluorescence intensities revealed a 
moderate increase in αTubulin acetylation in response 
to 3 μM LIMKi, and a significant increase in response 
to 10 µM LIMKi treatment, relative to DMSO vehicle 
control. These results indicate that the LIMK inhibitor 
affected microtubule organization and post-translational 
modification. 
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Figure 1: LIMK inhibition affects microtubule structures and acetylation. A. A549 non-small cell lung adenocarcinoma cells 
were treated with LIMKi at the indicated concentrations for 24 hours, then cell lysates were Western blotted for phosphorylated and total 
cofilin. Graph indicates mean + SEM (n = 3). B. A549 non-small cell lung adenocarcinoma cells were treated as indicated for 24 hours, 
then fixed and stained with αTubulin antibody. Scale bar = 20 µm. C. A549 cells were treated as indicated for 24 hours, then fixed and 
stained with αTubulin (red) and acetylated αTubulin (green) antibodies. Nuclear DNA was stained with DAPI (blue). Scale bar = 20 µm. 
Immunofluorescence staining intensity of acetylated αTubulin was quantified with ImageJ software using a fixed intensity threshold, and 
normalized to total αTubulin immunofluorescence intensity levels. Statistical significance was analyzed by one-way ANOVA and Dunnett’s 
post-hoc test (mean + SEM, n = 3).
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To investigate the role of LIMK in mitosis, 
we analyzed the effect of LIMKi on mitotic spindle 
morphology. A549 cells were treated for 24 hours with 
DMSO vehicle, 3 or 10 μM LIMKi, then fixed and 
stained with αTubulin antibody and the DNA stain 
4’,6-diamidino-2-phenylindole (DAPI). We observed 
significant alterations in spindle microtubule structure 
and organization with increasing LIMKi concentrations, 
including; decreased or complete loss of aster 
microtubules, defects in spindle microtubule integrity, 
defects in microtubule polymerization, or the appearance 
of monoastral spindles (Figure 2). To quantify these 
effects, > 10 representative mitotic cells per treatment were 
morphologically characterised for the above abnormalities 
and the percentage occurrence of each microtubule defect 
in three independent replicate experiments was determined 
(Figure 2). The occurrence of microtubule defects during 
mitosis progressively increased with increasing LIMKi 
concentration, with significant decreases in the percentage 
of normal cells with increasing LIMKi concentration 
(Figure 2). Therefore, we concluded that treatment with a 
LIMK inhibitory compound had a strong effect on cancer 
cell mitosis. 
Consistent with the sensitivity of A549 cells to 
LIMKi, active phosphorylated LIM kinases have been 
previously found to co-localise with γTubulin at mitotic 
cell centrosomes [34]. To test if LIMK activity was 
important for active LIMK localization and mitotic 
spindle assembly, we tested the effect of LIMKi on 
active phosphorylated LIMK (p-LIMK) and γTubulin co-
localization in mitotic A549 cells (Figure 3A). Treatment 
with 3 µM LIMKi had no effect on p-LIMK localization, 
indicating that p-LIMK localization to centrosomes is 
independent from LIMK activity (Figure 3B). Consistent 
with previous results [12], 3 µM LIMKi eliminated 
basal and induced cofilin phosphorylation, indicating 
inhibition of LIMK activity, while only slightly reducing 
LIMK phosphorylation (Figure 3C). Treatment with a 
low concentration of the vinca alkaloid Vincristine (5 
nM), which did not detectably affect spindle morphology 
[35] had a small effect on p-LIMK and γTubulin co-
localization (Figure 3B). The combination of 5 nM 
Vincristine and 3 µM LIMKi had a significant effect on 
p-LIMK and γTubulin co-localization greater than DMSO 
vehicle or Vincristine alone (Figure 3B). Moreover, 
immunofluorescence images show that combined LIMKi 
and vincristine treatment also had the strongest effect on 
spindle integrity, indicating possible co-operation between 
microtubules and LIMK function in mitosis (Figure 3A). 
Figure 2: LIMK inhibition affects microtubule assembly in mitotic spindles. A549 cells were treated as indicated for 24 
hours, then fixed and stained for DNA with DAPI (blue) and αTubulin (red) antibody. Representative images of each type of mitotic defect 
observed are presented. For each condition, > 10 randomly selected metaphase cells were scored per indicated treatment. Scale bar = 10 
µm. Statistical significance of changes in normal mitosis incidence were analyzed by one-way ANOVA and Tukey’s multiple comparison 
post-hoc test (mean + SEM, n = 3).
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Figure 3: LIMK inhibition disrupts mitotic spindle integrity. A. Co-localization of γTubulin (green) and phosphorylated LIMK 
(p-LIMK; red) was determined in A549 cells 24 hours after indicated treatments. Nuclear DNA was stained with DAPI (blue). B. Co-
localization was analyzed on 10 randomly selected metaphase cells per indicated treatment. Pearson correlations of protein co-localization 
were quantified for each analyzed nucleus. Statistical significance of changes in protein co-localization were analyzed by one-way ANOVA 
and Tukey’s multiple comparison post-hoc test (mean + SEM, n = 3). C. MCF-7 cells were treated with Adr (0.2 μg/ml) in the presence or 
absence of LIMKi (3 μM) for 24 h. Whole cell lysates were immunoblotted with antibodies against phospho-cofilin, cofilin, and phospho-
LIMK. Equivalent protein loading was confirmed by ERK2 immunoblotting.
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Cancer cell proliferation is inhibited by LIMKi 
combined with microtubule polymerization 
inhibitors
The effect of LIMKi combined with Vincristine on 
mitotic spindle integrity led us to test if LIMKi would have 
a combination effect on cancer cell proliferation. While 3 
μM LIMKi alone did not affect A549 cell numbers, when 
treated with a concentration range of Vincristine in the 
presence of 3 μM LIMKi or DMSO in a 3-day assay based 
Figure 4: LIMK inhibition combines with microtubule polymerization inhibition. A. A549 cells were treated with indicated 
concentrations of Vincristine in the presence of 3 µM LIMKi or DMSO for 72 hours, then cells were fixed with 4% paraformaldehyde and 
stained with DAPI. Nuclei were imaged and quantified relative to the number of cells treated with DMSO alone. Curve fitting was used 
to determine EC
50
 values (mean + SEM, n = 3). B. A549 cells were treated with combinations of two-fold serial dilutions of LIMKi and 
Vincristine, and relative cell viability determined by CellTiter-Glo® (mean + SEM, n = 3). C. Spontaneously immortalized wild-type (WT) 
and Limk2-/- mouse embryo fibroblasts (MEFs) were treated for 72 hours as indicated, and cell numbers relative to untreated controls used 
to determine EC
50
 values (mean + SEM, n = 3). D. The G2/M cell cycle profiles were determined by FACS of PI stained cells following 
72 hours treatments as indicated (mean + SEM, n = 3). E. The sub-G1 DNA content profiles were determined by FACS of PI stained cells 
following 72 hour treatments as indicated (mean + SEM, n = 3). F. A549 cells were treated with indicated concentrations of Vinorelbine or 
G. Colchicine in the presence of 3 µM LIMKi or DMSO for 72 hours, then cells were fixed with 4% paraformaldehyde and stained with 
DAPI. Nuclei were imaged and quantified relative to the number of cells treated with DMSO alone. Curve fitting was used to determine 
EC
50
 values (mean + SEM, n = 3).
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on counting remaining cell number, there was a ~2 fold 
decrease in Vincristine EC
50
 in the presence of LIMKi, 
indicating a synergistic cooperation between Vincristine 
and LIMKi (Figure 4A). By comparing the effects of 
fixed ratios of Vincristine (0.625-5 nM) and LIMKi (2.5-
20 µM) concentrations on cell viability as determined 
by CellTiter-Glo® Luminescent Cell Viability Assay, an 
average Combination Index of 0.77 + 0.02 indicating 
synergy was determined by the Chou-Talalay method 
[36] for LIMKi concentrations < 10 µM (Figure 4B). 
Furthermore, there was ~2-fold difference in Vincristine 
EC
50
 between spontaneously immortalized wild-type (WT) 
and Limk2-/- mouse embryo fibroblasts as determined 
by counting remaining cells (Figure 4C). To determine 
how the combined treatment of LIMKi and Vincristine 
decreased cell numbers, we profiled DNA content by 
fluorescence-activated cell sorting (FACS) of propidium 
iodide (PI) stained cells. The proportions of cells with 4N 
DNA content, indicative of G2/M cell cycle phases, were 
progressively increased with Vincristine concentration 
when combined with 3 µM LIMKi (Figure 4D, left panel) 
or with increased LIMKi concentration when combined 
with 5 nM Vincristine (Figure 4D, right panel) relative to 
DMSO vehicle control. In addition, the proportion of < 2N 
DNA content, typically a reflection of DNA fragmentation 
during apoptosis, progressively increased with increased 
Vincristine concentration when combined with 3 µM 
LIMKi (Figure 4E, left panel) or with increased LIMKi 
concentration when combined with 5 nM Vincristine 
(Figure 4E, right panel) relative to DMSO vehicle control. 
Taken together, these results indicate that the combined 
effect of LIMKi and a microtubule polymerization 
inhibitor was at least partially due to impaired mitosis, 
leading to impaired G2/M cell cycle progression and 
subsequent apoptosis. 
To determine whether this effect was specific for 
Vincristine, we tested additional microtubule-targeting 
drugs with and without LIMKi. The microtubule 
polymerization inhibitors Vinorelbine (Figure 4F) and 
Colchicine (Figure 4G) had similar ~2-fold decreases in 
EC
50
 in the presence of LIMKi. These results indicate that 
LIMKi synergizes with agents that target microtubule 
polymerization.
LIMKi potentiates kinase inhibitor reductions in 
proliferation
Given the consistent positive interactions between 
LIMKi and microtubule polymerization inhibitors, we 
wished to determine whether other cancer drug targets 
would also combine with LIMK inhibition to block 
cancer cell proliferation. A high-throughput screen was 
undertaken using the GSK published kinase inhibitor set 
(PKIS) of 366 small molecule kinase inhibitors [30]. A549 
cells were treated with half-log serial dilutions of library 
compounds in the presence of 3 μM LIMKi or DMSO. 
Compounds having either no cytotoxic effect (Figure 5A), 
or an effect that did not reach 50% alone (Figure 5B), but 
achieved more than 50% reduction in relative cell number 
when combined with 3 µM LIMKi were selected as 20 
hits (Supplemental Table 1). Compounds that produced 
a greater than 2-fold decrease in absolute EC
50
 when 
combined with 3 µM LIMKi (Figure 5C) were selected 
as 43 additional hits (Figure 5D; Supplemental Table 2). 
Remaining compounds either did not fit these criteria 
selection criteria (Supplemental Table 3) or were without 
combination effects (Supplemental Table 4).
To identify common drug targets from the selected 
hits, kinase inhibitor selectivity data for the 63 hits from 
GSK were clustered by pairwise average-linkage cluster 
analysis with the dot product distance option using TM4 
[37] (Figure 5E), with color gradations ranging from 0% 
(black) to 100% inhibition (yellow). Amongst the most 
frequently occurring designated targets were VEGFR or 
VEGFR/TIE2, GSK3, AKT, CDK2 and IGF1R. However, 
the broad specificity of these inhibitors makes it difficult 
to draw conclusions about the contributions of individual 
kinases to the observed combination effects. In contrast, 
there were some clusters of kinase inhibitors with narrow 
selectivity profiles that highlight certain kinase targets as 
possibly indicating biological interactions with LIMK 
signaling, including PLK1, RAF, EGFR/ErbB2 and p38. 
These results indicate that there may be mechanism-based 
effective drug combinations with LIMK inhibitors, in 
addition to microtubule polymerization inhibitors, that 
could be characterized further for potential clinical use.
Discovery of novel LIMK inhibitors
Given the potential for the use of LIMK inhibitors 
as cancer chemotherapeutics, a high-throughput drug 
discovery and medicinal chemistry program was 
undertaken. Details of the screening methodology and 
description of initial hit matter were described in [38]. 
Following iterative rounds of lead optimization medicinal 
chemistry and in vitro enzyme assays, two compounds 
were developed with potent LIMK inhibitory activity; 
N-{5-[3-(4-Methoxy-2-trifluoromethyl-phenyl)-pyridin-
4-yl]-hiazol-2-yl}-isobutyramide (CRT0105446; Figure 
6A) and 4-{5-[3-(2-Chloro-4-methyl-phenyl)-pyridin-4-
yl]-thiazol-2-ylamino}-phenol (CRT0105950; Figure 6B). 
Details of their chemical synthesis are described in Charles 
et al. [39]. The in vitro IC
50
 values for LIMK1 and LIMK2 
were 8 nM and 32 nM respectively for CRT0105446, 
and 0.3 nM and 1 nM respectively for CRT0105950. 
These and additional physiochemical parameters are in 
Supplemental Table 5. Kinase selectivity was profiled 
for 442 kinases using KINOMEscan technology [31] at 
10 µM CRT0105446 and CRT0105950 (Supplemental 
Table 6), and mapped onto a kinome phylogenetic 
tree [32] in Figure 6A and 6B. To compare specificity 
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Figure 5: LIMK inhibition combination with Published Kinase Inhibitor Set compounds. A. Cell numbers, relative to 
DMSO control, were used to determine EC
50
 values (indicated with dotted red lines) after 72 hours of treatment with DMSO or 3 µM 
LIMKi combined with GW784684X, B. GW1023156A or C. GW852849X as indicated. D. Log2 fold-change ratios of absolute EC50 values 
in the presence or absence of 3 µM LIMKi were plotted for each compound. Red dotted line indicates a 2-fold increase in compound 
sensitivity in the presence of 3 µM LIMKi. E. In vitro selectivity data of the selected 63 compounds against 224 kinase targets was 
used for unsupervised pairwise average-linkage cluster analysis with dot product distance option using Multiexperiment Viewer software. 
Percentage target inhibition is indicated in gradations from 0% (black) to 100% (yellow).
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Figure 6: Discovery of novel LIMK inhibitors CRT0105446 and CRT0105950. A. CRT0105446 structure and percentage 
inhibition of 442 kinases at 10 μM mapped onto a kinome phylogenetic tree. Kinases inhibited >25% to 50% have yellow circles, 51% to 
75% have orange circles, and >76% have red circles. In each case, the size of the circle is proportional to percentage inhibition. LIMK1 
and LIMK2 positions are indicated in blue. Illustration reproduced courtesy of Cell Signaling Technology, Inc. (www.cellsignal.com). B. 
CRT0105950 structure and kinome selectivity mapping as described above. C. Selectivity S(35) scores were compared for CRT0105446 
and CRT0105950 (blue) with 38 inhibitors, including 7 FDA-licenced compounds (pink). Inset graph indicates S(1), S(10) and S(35) scores 
for CRT0105446 and CRT0105950.
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quantitatively, CRT0105446 and CRT0105950 S(35) 
selectivity scores (Figure 6C; indicated in blue), a ratio of 
kinases inhibited by >65% relative to the total number of 
kinases, were compared to S(35) values for 38 additional 
kinase inhibitors, including 7 FDA licenced drugs, at 10 
µM (Figure 6C). Furthermore, the inset graph in Figure 
6C depicting S(1) (i.e. proportion of kinases inhibited by 
99%), S(10) (proportion of kinases inhibited by 90%) and 
S(35) selectivity scores depicts the greater selectivity of 
CRT0105446 relative to the more potent CRT0105950.
We compared the cell-based potencies of 
CRT0105446 and CRT0105950 with LIMKi using 
three read-outs: cofilin phosphorylation, αTubulin 
acetylation and three-dimensional (3-D) extracellular 
matrix invasion. All three compounds were equivalently 
potent at increasing αTubulin acetylation (Figure 7A) 
and decreasing cofilin phosphorylation (Figure 7B) in 
A549 lung cancer cells. To more precisely determine cell-
Figure 7: Comparison of CRT0105446 and CRT0105950 effects on LIMK functions in cells. A. A549 cells were treated 
with indicated concentrations of LIMK inhibitors for 24 hours, then blotted for acetylated αTubulin (green) and αTubulin (red). Ratios of 
acetylated/total αTubulin were determined and plotted relative to vehicle treated cells (mean + SEM, n = 3). B. A549 cells were treated 
as above, then blotted for phosphorylated cofilin (red) and total cofilin (green). Ratios of phosphorylated/total cofilin were determined 
and plotted relative to vehicle treated cells (mean + SEM, n = 3). C. MCF7 breast cancer cells were treated with 2 µg/mL Doxorubicin 
plus DMSO or indicated concentrations of LIMK inhibitors for 18 hours, then cells were fixed and stained for phosphorylated cofilin. 
Single cell fluorescence intensities were determined and curve fitted to determine EC
50
 values (mean + SEM, n = 8). D. MDAMB231 
breast cancer cells were treated with indicated concentrations of LIMKi or E. CRT0105950 for 24 hours, then cell lysates prepared and 
immunoblotted with antibodies against phospho-cofilin and αTubulin. F. Confocal images taken at 10 µm intervals through 3-D matrigel 
revealed significant inhibition of MDAMB231 breast cancer cell invasion above 60 µm by 3 µM LIMKi, CRT0105446 and CRT0105950 
relative to DMSO control. Statistical significance was analyzed by one-way ANOVA and Dunnett’s post-hoc test (mean + SEM, N = 3-8).
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based LIMK inhibitor activity, MCF7 breast cancer cells 
were treated with 2 µg/mL doxorubicin, which strongly 
increases cofilin phosphorylation through increased 
p53-mediated transcription of LIMK2 and RhoC genes 
[12] to increase the dynamic range and signal-to-noise 
ratio of the assay, and varying concentrations of LIMK 
inhibitors for 18 hr, then cells were fixed and stained for 
immunofluorescence determination of phosphorylated 
cofilin intensity. Dose-response analysis revealed that all 
three compounds inhibited cofilin phosphorylation, with 
LIMKi being ~2-fold more potent than CRT0105950 and 
7-fold more potent than CRT0105446 in this assay format 
(Figure 7C). We additionally established that LIMK 
inhibition resulted in decreased cofilin phosphorylation 
in MDAMB231 human breast cancer cells by comparing 
the effect of a range of LIMKi and CRT0105950 
concentrations on phospho-cofilin levels. As shown 
in Figures 7D and 7E, both inhibitors induced dose-
dependent decreases in cofilin phosphorylation. Finally, 
the inverse invasion of 3-D matrigel by MDAMB231 
breast cancer cells above a 60 µm cut-off was significantly 
inhibited by 3 µM LIMKi, CRT0105446 and CRT0105950 
(Figure 7F), consistent with our previous observations 
using LIMKi [9]. These results are consistent with all 
three inhibitors being potent inhibitors of LIMK activity 
in cells.
Identification of cancer cells sensitive to LIMK 
inhibitors
To identify cancer cell types with significant 
sensitivity to chemical LIMK inhibitors, a screen 
was performed on 656 cancer cell lines [40] with 
CRT0105950 and CRT0105446. Each inhibitor was 
tested at concentrations from 0.3-10 µM, and cell 
numbers determined as described in [40]. By comparing 
calculated EC
50
 values for cell lines (Supplemental Tables 
7-8) within a given cancer type against all cancer cell 
lines (Supplemental Table 9-10), significantly (p < 0.05) 
sensitive and resistant cancer types were identified. Figure 
8A shows natural log EC
50
 values (in µM) of CRT0105950 
for each cell line within each cancer type, with a red line 
indicating mean EC
50
 and arranged in order of their mean 
EC
50
 from low to high values. Relative to the mean EC
50
 
of CRT0105950 for all cancer cell lines (19.2 µM), there 
were 5 cancer types that were significantly sensitive and 5 
cancer types that were significantly resistant (shown with 
green dots). Similarly, 3 cancer types were significantly 
sensitive and 5 were significantly resistant (Figure 8B, 
orange dots), relative to the mean EC
50
 of all cancer cells 
to CRT0105446 (238 µM).
 To determine which cancer types were most 
likely affected by the on-target effects of CRT0105446 
and CRT0105950, we plotted the mean EC
50
 values 
for both drugs of each cancer type (Figure 9). Cancer 
types that were significantly sensitive or resistant to 
both drugs are indicated with red dots, while those 
cancer types significantly affected by CRT0105446 are 
depicted with orange dots and those significantly affected 
by CRT0105950 are shown with green dots. Deming 
regression indicates that the slope of a fitted line was 
significantly different from 0, indicating that there was 
a direct relationship between cancer type responses to 
both drugs. This analysis revealed that neuroblastoma, 
rhabdomyosarcoma and kidney cancer cells were 
significantly sensitive to both LIMK inhibitors, with 6 
additional cancer types being sensitive to either inhibitor 
and trending towards sensitivity to the other (e.g. Ewing’s 
sarcoma, osteosarcoma and additional soft tissue cancer 
cell lines). Burkitt lymphoma and B cell lymphoma 
were the only significantly resistant cancer types, with 4 
additional cancer types being sensitive to either inhibitor 
and trending towards sensitivity towards the other (e.g. 
Hodgkin lymphoma and myeloma).
To validate the sensitivity of neuroblastoma cells to 
LIMK inhibitors, we tested 6 neuroblastoma cell lines for 
their responses to LIMKi (Figure 10A). When the mean 
natural log EC
50
 values of LIMKi for these 6 cell lines 
were compared to CRT0105950 and CRT0105446 EC
50
 
values for the 27 neuroblastoma cell lines from the screen, 
both LIMKi and CRT0105950 were significantly more 
effective than CRT0105446 but were not different from 
each other (Figure 10B), consistent with their rank order 
of potencies for inhibition of cofilin phosphorylation, 
tubulin acetylation and matrix invasion (Figure 7). 
To corroborate the requirement for LIMK activity in 
neuroblastoma cells, we knocked down LIMK1 and 
LIMK2, either by combining two siRNA oligonucleotides 
(LIMK1+LIMK2) or using an siRNA oligonucleotide 
(panLIMK) that reduces expression of both proteins, in 
SK-N-AS and SK-N-SH cells (Figure 10C). Relative to a 
non-targeting control (NTC) oligonucleotide, both forms 
of LIMK knockdown significantly reduced neuroblastoma 
cell viability in SK-N-AS cells (Figure 10D) and SK-N-
SH cells (Figure 10E).
DISCUSSION
The LIM kinases have well characterized roles in 
regulating the actin cytoskeleton through their regulation 
of cofilin activity, and consequently have been regarded 
as potential targets for anti-metastasis therapy [1, 15, 
41]. It has recently emerged that LIMK1 and LIMK2 
also influence microtubule dynamics and have important 
functions in mitosis [4, 5, 13], which is consistent with 
LIMK inhibitors being potential cancer therapeutics. In the 
present study, the effect of inhibiting LIMK activity on 
microtubule structures and mitosis has been validated, and 
combinations with microtubule destabilizing drugs shown 
to act synergistically. By screening the PKIS compound 
library, additional potential drug combinations with 
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Figure 8: Evaluation of cancer cell line sensitivities to LIMK inhibitors. A. A total of 656 cancer cell lines, divided into 54 
cancer types, were treated with 9 concentrations of a 2-fold dilution series of CRT0105950 (top concentration = 10 μM). After 72 hours, 
cell density was measured, EC
50
 values calculated and MANOVA performed to identify cancer types significantly (p < 0.05; green dots) 
sensitive or resistant to CRT109590 relative to all cancers considered together. Red lines indicate mean EC
50
 for each cancer type, and red 
dotted line showing mean EC
50
 for all cancers. B. Sensitivity or resistance to CRT0105446 was determined as described above. Cancer 
types significantly (p < 0.05) different from all cancers indicated with orange dots.
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LIMK inhibition were identified, including EGFR and 
Raf kinases. Previous research on the chemosensitivity 
of 39 human cancer cell lines to 55 anti-cancer 
drugs revealed that elevated LIMK2 expression was 
significantly correlated to resistance to 18 drugs (including 
topoisomerase I inhibitors, bleomycin derivatives and 
anthracyclines such as doxorubicin) independent of the 
tissue of origin [10]. We also showed that DNA damaging 
agents induce LIMK2 expression via p53, while inhibition 
or knockdown of LIMK2 activity increased sensitivity 
to these chemotherapeutics [12]. Taken together, these 
findings are consistent with LIMK activity being an 
important contributory factor to drug resistance.
To identify cancer types sensitive to LIMK 
inhibition, 656 cancer cell lines were screened with dose 
ranges of CRT0105446 and CRT0105950 that enabled 
statistical comparison of drug sensitivity. Three cancer 
types were significantly sensitive to both LIMK inhibitors; 
rhabdomyosarcoma, neuroblastoma and kidney cancer. 
Interestingly, previous research showed that neuroblastoma 
cells selected for resistance to Vincristine had increased 
LIMK2 expression, while LIMK2 knockdown led to the 
formation of abnormal mitotic spindles and sensitized 
neuroblastoma cells to Vincristine and Vinblastine [13]. 
Figure 9: Comparison of cancer cell line sensitivities to LIMK inhibitors. The mean EC
50
 values for each cancer type to 
CRT0105950 and CRT0105446 were plotted, with mean EC
50 
for all cancers indicated as a dotted green line for CRT0105950 and an orange 
dotted line for CRT0105446. Red dots indicate cancer types significantly (p < 0.05) resistant or sensitive to both inhibitors, while green 
dots indicate sensitivity or resistance to CRT0105950 alone and orange dots indicate sensitivity or resistance to only CRT0105446. Deming 
regression indicates that there is a significant (p = 0.0293) relationship between the sensitivities to both drugs.
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Figure 10: Sensitivity of neuroblastoma cell lines to LIMK inhibition. A. Cell viability relative to DMSO vehicle control was 
determined by CellTiter-Glo® after treatment of neuroblastoma cell lines with indicated concentrations of LIMKi. Figure legend shows the 
calculated EC
50
 for each cell line (mean + SEM, n = 3). B. Comparison of the sensitivities of 27 neuroblastoma cell lines to CRT0105950 and 
CRT0105446 with the sensitivity of 6 neuroblastoma cell lines to LIMKi. Line indicates mean EC
50
 for each LIMK inhibitor. Significance 
was analyzed by one-way ANOVA and post-hoc Tukey’s test. C. SK-N-AS and SK-N-SH neuroblastoma cell lines were left untreated or 
transfected with non-targeting (NTC) siRNA, a combination of LIMK1 and LIMK2 siRNAs (LIMK1+LIMK2) or a dual LIMK1/LIMK2 
targeting siRNA as indicated, then 72 hours later cell lysates were prepared and immunoblotted for LIMK1 and LIMK2. αTubulin blotting 
allowed for comparison of protein loading. D. Relative cell viability was determined for SK-N-AS and E. SK-N-SH cells 72 hours after 
siRNA transfection by CellTiter-Glo® viability assay and normalized to untransfected cells in each experimental replicate. Significance was 
analyzed by one-way ANOVA and post-hoc Tukey’s test.
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Furthermore, LIMK2 knockdown increased cell cycle 
arrest apoptosis induced by microtubule targeting drugs 
[11]. These results are consistent with a prominent role for 
LIMK signalling in neuroblastoma.
The two novel LIMK inhibitors described in the 
present study, CRT0105446 and CRT0105950, are potent 
inhibitors of LIMK1 and LIMK2 that will enable further 
development of LIMK-targeted cancer therapy.
MATERIALS AND METHODS
Cell line culture and validation
A549 non-small cell lung adenocarcinoma, 
MDAMB231 and MCF7 breast cancer and neuroblastoma 
cell lines (MHH-NB-11, LAN-6, SH-SY5Y, SK-N-BE-2c, 
SK-N-AS, SK-N-SH, SK-N-MC, IMR-32) were cultured 
according to ATCC guidelines. Cell identities were 
validated using the GenePrint 10 system STR multiplex 
assay (Promega) that amplifies 9 tetranucleotide repeat 
loci and Amelogenin gender determining marker.
Antibodies
αTubulin (Sigma, Cell Signaling Technology), 
acetylated-αTubulin (Novus Biologicals), pLIMK (Thr508 
- LIMK1, Thr505 - LIMK2; Abcam or Cell Signaling 
Technology), γTubulin (Sigma), phospho-cofilin (Ser3; 
Cell Signaling Technology), cofilin (Abcam) and ERK2 
(Ab122; CJ Marshall, Institute of Cancer Research, 
London).
Western blotting
Cells were lysed with 500 µl of lysis buffer (1x Tris-
buffered saline (TBS), 1% Triton-X, 1 nM EDTA, 0.2 
mM Na3VO4, 20 mM NaF, 1 mM PMSF, and cOmplete 
Mini protease inhibitor cocktail (Roche)) per 10 cm 
plate. Lysates were cleared by 10-minute centrifugation 
and Western blotted [12] with corresponding antibodies. 
Quantification of Western blots was performed directly 
without signal amplification or X-ray film using infra-
red emitting secondary antibodies and detection with an 
ODYSSEY® infrared imaging system (LI-COR).
Immunofluorescence
Cells were plated on glass coverslips, 24 hours 
after treatment, cells were fixed and antibody stained as 
described [9]. Images were acquired on a Zeiss710 laser-
scanning confocal microscope and processed in ZEN2010 
(Zeiss).
Immunofluorescence image quantification
Immunofluorescence intensity of acetylated-
αTubulin was quantified in ImageJ using fixed intensity 
threshold, and normalized to total αTubulin. Co-
localization analysis was performed on ten mitotic cell 
images per treatment per experiment using Volocity 
(PerkinElmer). Pearson correlation of protein co-
localization was quantified for each cell analysed.
To quantify mitotic cell morphological changes, 
pictures of > 10 randomly-selected cells in metaphase 
were taken per treatment per experiment and scored 
based on their morphology as indicated. Percentages of 
cells with each defect were quantified for each treatment 
condition and reported as mean + SEM from triplicate 
determinations. 
Cytotoxicity assay
A549 cells were plated in 96-well plates at 2000 
cells per well, 24 hours before treatment. Cells were 
treated with serial dilutions of indicated compounds 
alone or in the presence of 3 µM LIMKi or DMSO, 
for 72 hours. Surviving cells were fixed with 4% 
paraformaldehyde and stained with 250 ng/ml DAPI. 
Experiments were repeated with three independent 
replicate experiments. Nuclei were imaged on a High 
Content Imaging Operetta system (PerkinElmer) and 
quantified using Harmony® High Content Imaging and 
Analysis Software (PerkinElmer). Cell numbers were 
plotted as percent change from DMSO-treated control and 
EC
50
 values were calculated from dose-response curves 
using Prism 5 (GraphPad). Drug combination synergy 
was determined by treating cells with serial dilutions 
of LIMKi (2.5-20 µM) and Vincristine (0.625-5 nM) 
alone or in 4X4 combinations, and quantifying cells 72 
hours using CellTiter-Glo® Luminescent Cell Viability 
Assay (Promega), following manufacturer’s protocol. 
Combination index and effect parameters were determined 
with CalcuSyn [36]. Neuroblastoma cell viability was 
quantified using CellTiter-Glo® Luminescent Cell Viability 
Assay (Promega), following manufacturer’s protocol.
Sub-G1 and G2/M quantification
Cells were plated in 6 well plates at 5x105 cells/well 
and treated the next day with indicated drugs for 72 hours. 
Percentage cells with sub-G1 DNA content or in G2/M 
phase were measured and analyzed as described [12].
PKIS compound screen
Cells were plated at 350 cells per well in 384-well 
plates, in 5 technical replicates. 24 hours after plating, cells 
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were treated with serial dilutions of indicated compounds 
(ranging from 0.005 to 10 µM in half-log dilutions) 
alone or in the presence of 3 µM LIMKi or DMSO, for 
72 hours. Vincristine was used as a positive control and 
DMSO (final 0.4%) was used as a negative control. Cells 
were fixed, stained with DAPI, and nuclei of surviving 
cells quantified as in the cytotoxicity assay. Results were 
plotted as percent change in cell number relative to the 
median DMSO alone-treated cell number and absolute 
EC
50
 values were calculated for each compound in the 
presence of LIMKi or DMSO control using the Vortex 
software analysis program. 
Synthesis of CRT0105446 and CRT0105950
Discovery and synthesis of CRT0105446 and 
CRT0105950 as described in Charles et al. [39].
Kinase selectivity profiling
Selectivity profiling was undertaken by Ambit (now 
DiscoveRx) as described in [42].
Cofilin phosphorylation quantification
MCF7 human breast cancer cells were plated at 
5x103 cells/well in black polystyrene glass-bottomed 
96 well plates and treated the next day with 0.2 µg/mL 
doxorubicin plus indicated LIMK inhibitor concentrations 
for 18 hours. Cells were washed, fixed with 4% 
paraformaldehyde, permeabilized with 0.5% Triton 
X-100 (v/v) and blocked for 1 hour with 1% BSA (w/v). 
Fixed cells were stained with rabbit antibody against 
phospho-Ser3 cofilin, then Alexa 488 anti-rabbit antibody 
(Invitrogen), Texas red Phalloidin (Molecular Probes) 
and DAPI (Sigma). After washing, cells were imaged on 
a High Content Imaging Operetta system (PerkinElmer) 
and phospho-Ser3 cofilin fluorescence intensity for each 
cell quantified using Harmony® High Content Imaging 
and Analysis Software (PerkinElmer), and plotted as 
percent change from DMSO alone-treated control for 
eight independent replicate determinations. EC
50
 values 
were calculated from dose-response curves using Prism 
5 (GraphPad).
Inverse invasion assay
MDAMB231 human breast cancer cell inverse 
invasion was assayed as described in [9].
Cancer cell line screen
Cancer cell line screening as described [40, 43].
siRNA knock-down
SK-N-AS or SK-N-SH cells were transiently 
transfected in suspension with indicated siRNA 
oligonucleotides at 25 nmoles per well, using 
DreamFectTM Gold transfection reagent (OZ Biosciences) 
according to manufacturer’s instructions, and plated at 
500 cells per well in 96-well plates and incubated for 
72 hours for determination of cell viability by CellTiter-
Glo® Luminescent Cell Viability Assay (Promega) 
according to manufacturer’s instructions. LIMK1 and 
LIMK2 ON-TARGETplus siRNA SMARTpools (Thermo 
Scientific); pan-LIMK siRNA, sense strand sequence: 
5’-AGGCTATCAAGGTGACACA-3’; NTC (non-
targeting control) siRNA - (Thermo Scientific). For knock-
down validation, 4,000 transfected cells from each assay 
were plated in 24-well plates and lysed after 72 hours. 
LIMK1 and LIMK2 protein levels were determined by 
Western blotting, with αTubulin blotting allowing for 
comparison of protein loading. 
Statistical analysis
All other statistical analyses were performed with 
Prism5 (GraphPad).
ACKNOWLEDGMENTS
Thanks to GSK for provision of PKIS.
CONFLICTS OF INTEREST
The authors have no conflicts of interest to declare.
GRANT SUPPORT
Funded by Cancer Research UK (A12478, A12966, 
A18276).
REFERENCES
1. Scott RW and Olson MF. LIM kinases: function, regulation 
and association with human disease. J Mol Med. 2007; 
85:555-568.
2. Bernard O. Lim kinases, regulators of actin dynamics. Int J 
Biochem Cell Biol. 2007; 39:1071-1076.
3. Yang N, Higuchi O, Ohashi K, Nagata K, Wada 
A, Kangawa K, Nishida E and Mizuno K. Cofilin 
phosphorylation by LIM-kinase 1 and its role in Rac-
mediated actin reorganization. Nature. 1998; 393:809-812.
4. Oku Y, Tareyanagi C, Takaya S, Osaka S, Ujiie H, Yoshida 
K, Nishiya N and Uehara Y. Multimodal effects of small 
molecule ROCK and LIMK inhibitors on mitosis, and 
their implication as anti-leukemia agents. PLoS One. 2014; 
Oncotarget38485www.impactjournals.com/oncotarget
9:e92402.
5. Mardilovich K, Gabrielsen M, McGarry L, Orange C, Patel 
R, Shanks E, Edwards J and Olson MF. Elevated LIM 
kinase 1 in nonmetastatic prostate cancer reflects its role 
in facilitating androgen receptor nuclear translocation. Mol 
Cancer Ther. 2015; 14:246-258.
6. Prudent R, Vassal-Stermann E, Nguyen CH, Pillet C, 
Martinez A, Prunier C, Barette C, Soleilhac E, Filhol 
O, Beghin A, Valdameri G, Honore S, Aci-Seche S, et 
al. Pharmacological inhibition of LIM kinase stabilizes 
microtubules and inhibits neoplastic growth. Cancer Res. 
2012; 72:4429-4439.
7. Vlecken DH and Bagowski CP. LIMK1 and LIMK2 are 
important for metastatic behavior and tumor cell-induced 
angiogenesis of pancreatic cancer cells. Zebrafish. 2009; 
6:433-439.
8. Morin P, Wickman G, Munro J, Inman GJ and Olson MF. 
Differing contributions of LIMK and ROCK to TGFbeta-
induced transcription, motility and invasion. Eur J Cell Biol. 
2011; 90:13-25.
9. Scott RW, Hooper S, Crighton D, Li A, Konig I, Munro 
J, Trivier E, Wickman G, Morin P, Croft DR, Dawson J, 
Machesky L, Anderson KI, et al. LIM kinases are required 
for invasive path generation by tumor and tumor-associated 
stromal cells. J Cell Biol. 2010; 191:169-185.
10. Dan S, Tsunoda T, Kitahara O, Yanagawa R, Zembutsu H, 
Katagiri T, Yamazaki K, Nakamura Y and Yamori T. An 
Integrated Database of Chemosensitivity to 55 Anticancer 
Drugs and Gene Expression Profiles of 39 Human Cancer 
Cell Lines. Cancer Res. 2002; 62:1139-1147.
11. Gamell C, Schofield AV, Suryadinata R, Sarcevic B and 
Bernard O. LIMK2 mediates resistance to chemotherapeutic 
drugs in neuroblastoma cells through regulation of drug-
induced cell cycle arrest. PLoS One. 2013; 8:e72850.
12. Croft DR, Crighton D, Samuel MS, Lourenco FC, Munro J, 
Wood J, Bensaad K, Vousden KH, Sansom OJ, Ryan KM 
and Olson MF. p53-mediated transcriptional regulation 
and activation of the actin cytoskeleton regulatory RhoC to 
LIMK2 signaling pathway promotes cell survival. Cell Res. 
2011; 21:666-682.
13. Po’uha ST, Shum MS, Goebel A, Bernard O and Kavallaris 
M. LIM-kinase 2, a regulator of actin dynamics, is involved 
in mitotic spindle integrity and sensitivity to microtubule-
destabilizing drugs. Oncogene. 2010; 29:597-607.
14. Chen Q, Jiao D, Hu H, Song J, Yan J, Wu L and Xu LQ. 
Downregulation of LIMK1 level inhibits migration of lung 
cancer cells and enhances sensitivity to chemotherapy 
drugs. Oncol Res. 2013; 20:491-498.
15. Manetti F. Recent Findings Confirm LIM Domain Kinases 
as Emerging Target Candidates for Cancer Therapy. Curr 
Cancer Drug Targets. 2012; 12:543-560.
16. Prudnikova TY, Rawat SJ and Chernoff J. Molecular 
Pathways: Targeting the Kinase Effectors of RHO-Family 
GTPases. Clin Cancer Res. 2015; 21:24-29.
17. Mardilovich K, Olson MF and Baugh M. Targeting Rho 
GTPase signaling for cancer therapy. Future Oncol. 2012; 
8:165-177.
18. Huang M, Shen A, Ding J and Geng M. Molecularly 
targeted cancer therapy: some lessons from the past decade. 
Trends Pharmacol Sci. 2014; 35:41-50.
19. Jego G, Hazoume A, Seigneuric R and Garrido C. Targeting 
heat shock proteins in cancer. Cancer Lett. 2013; 332:275-
285.
20. Hall A. The cytoskeleton and cancer. Cancer Metastasis 
Rev. 2009; 28:5-14.
21. Ross-Macdonald P, de Silva H, Guo Q, Xiao H, Hung CY, 
Penhallow B, Markwalder J, He L, Attar RM, Lin TA, Seitz 
S, Tilford C, Wardwell-Swanson J, et al. Identification of 
a nonkinase target mediating cytotoxicity of novel kinase 
inhibitors. Mol Cancer Ther. 2008; 7:3490-3498.
22. Yin Y, Zheng K, Eid N, Howard S, Jeong JH, Yi F, Guo 
J, Park CM, Bibian M, Wu W, Hernandez P, Park H, Wu 
Y, et al. Bis-aryl urea derivatives as potent and selective 
LIM kinase (Limk) inhibitors. J Med Chem. 2015; 58:1846-
1861.
23. Mashiach-Farkash E, Rak R, Elad-Sfadia G, Haklai R, 
Carmeli S, Kloog Y and Wolfson HJ. Computer-based 
identification of a novel LIMK1/2 inhibitor that synergizes 
with salirasib to destabilize the actin cytoskeleton. 
Oncotarget. 2012; 3:629-639.
24. Goodwin NC, Cianchetta G, Burgoon HA, Healy J, Mabon 
R, Strobel ED, Allen J, Wang S, Hamman BD and Rawlins 
DB. Discovery of a Type III Inhibitor of LIM Kinase 2 That 
Binds in a DFG-Out Conformation. ACS Med Chem Lett. 
2015; 6:53-57.
25. He L, Seitz SP, Trainor GL, Tortolani D, Vaccaro W, Poss 
M, Tarby CM, Tokarski JS, Penhallow B, Hung CY, Attar 
R and Lin TA. Modulation of cofilin phosphorylation by 
inhibition of the Lim family kinases. Bioorg Med Chem 
Lett. 2012; 22:5995-5998.
26. Li R, Doherty J, Antonipillai J, Chen S, Devlin M, Visser K, 
Baell J, Street I, Anderson RL and Bernard O. LIM kinase 
inhibition reduces breast cancer growth and invasiveness 
but systemic inhibition does not reduce metastasis in mice. 
Clin Exp Metastasis. 2013; 30:483-495.
27. Rak R, Haklai R, Elad-Tzfadia G, Wolfson HJ, Carmeli S 
and Kloog Y. Novel LIMK2 Inhibitor Blocks Panc-1 Tumor 
Growth in a mouse xenograft model. Oncoscience. 2014; 
1:39-48.
28. Petrilli A, Copik A, Posadas M, Chang LS, Welling DB, 
Giovannini M and Fernandez-Valle C. LIM domain kinases 
as potential therapeutic targets for neurofibromatosis type 2. 
Oncogene. 2014; 33:3571-3582.
29. Park JB, Agnihotri S, Golbourn B, Bertrand KC, Luck A, 
Sabha N, Smith CA, Byron S, Zadeh G, Croul S, Berens M 
and Rutka JT. Transcriptional profiling of GBM invasion 
genes identifies effective inhibitors of the LIM kinase-
Cofilin pathway. Oncotarget. 2014; 5:9382-9395.
Oncotarget38486www.impactjournals.com/oncotarget
30. Drewry DH, Willson TM and Zuercher WJ. Seeding 
collaborations to advance kinase science with the GSK 
Published Kinase Inhibitor Set (PKIS). Curr Top Med 
Chem. 2014; 14:340-342.
31. Karaman MW, Herrgard S, Treiber DK, Gallant P, Atteridge 
CE, Campbell BT, Chan KW, Ciceri P, Davis MI, Edeen 
PT, Faraoni R, Floyd M, Hunt JP, et al. A quantitative 
analysis of kinase inhibitor selectivity. Nat Biotech. 2008; 
26:127-132.
32. Manning G, Whyte DB, Martinez R, Hunter T and 
Sudarsanam S. The Protein Kinase Complement of the 
Human Genome. Science. 2002; 298:1912-1934.
33. Piperno G, LeDizet M and Chang XJ. Microtubules 
containing acetylated alpha-tubulin in mammalian cells in 
culture. J Cell Biol. 1987; 104:289-302.
34. Chakrabarti R, Jones JL, Oelschlager DK, Tapia T, Tousson 
A and Grizzle WE. Phosphorylated LIM kinases colocalize 
with gamma-tubulin in centrosomes during early stages of 
mitosis. Cell Cycle. 2007; 6:2944-2952.
35. Jordan MA, Thrower D and Wilson L. Effects of 
vinblastine, podophyllotoxin and nocodazole on mitotic 
spindles. Implications for the role of microtubule dynamics 
in mitosis. J Cell Sci. 1992; 102 ( Pt 3):401-416.
36. Chou T-C. Theoretical Basis, Experimental Design, and 
Computerized Simulation of Synergism and Antagonism in 
Drug Combination Studies. Pharmacol Rev. 2006; 58:621-
681.
37. Saeed AI, Sharov V, White J, Li J, Liang W, Bhagabati N, 
Braisted J, Klapa M, Currier T, Thiagarajan M, Sturn A, 
Snuffin M, Rezantsev A, et al. TM4: a free, open-source 
system for microarray data management and analysis. 
BioTechniques. 2003; 34:374-378.
38. Mezna M, Wong AC, Ainger M, Scott RW, Hammonds 
T and Olson MF. Development of a High-Throughput 
Screening Method for LIM Kinase 1 Using a Luciferase-
Based Assay of ATP Consumption. J Biomol Screen. 2011; 
17:460-468.
39. Charles MD, Brookfield JL, Ekwuru CT, Stockley M, 
Dunn J, Pritchard M, Hammonds T, Trivier E, Greenland 
G, Wong AC, Cheasty A, Boyd S, Crighton D, et al. 
Discovery, development and SAR of aminothiazoles as 
LIMK inhibitors with cellular anti-invasive properties. J 
Med Chem. 2015. DOI: 10.1021/acs.jmedchem.5b01242
40. Garnett MJ, Edelman EJ, Heidorn SJ, Greenman CD, Dastur 
A, Lau KW, Greninger P, Thompson IR, Luo X, Soares J, 
Liu Q, Iorio F, Surdez D, et al. Systematic identification of 
genomic markers of drug sensitivity in cancer cells. Nature. 
2012; 483:570-575.
41. Manetti F. LIM kinases are attractive targets with many 
macromolecular partners and only a few small molecule 
regulators. Med Res Rev. 2011; 32:968-998.
42. Fabian MA, Biggs WH, Treiber DK, Atteridge CE, 
Azimioara MD, Benedetti MG, Carter TA, Ciceri P, Edeen 
PT, Floyd M, Ford JM, Galvin M, Gerlach JL, et al. A 
small molecule-kinase interaction map for clinical kinase 
inhibitors. Nat Biotech. 2005; 23:329-336.
43. Yang W, Soares J, Greninger P, Edelman EJ, Lightfoot 
H, Forbes S, Bindal N, Beare D, Smith JA, Thompson IR, 
Ramaswamy S, Futreal PA, Haber DA, et al. Genomics 
of Drug Sensitivity in Cancer (GDSC): a resource for 
therapeutic biomarker discovery in cancer cells. Nucleic 
Acids Res. 2013; 41:D955-961.
